Related Experiment Video

Updated: Apr 12, 2026

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

14.3K

Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway

Ems Litwinoff1, C Hurtado Del Pozo1, R Ramasamy1

  • 1Diabetes Research Program, Division of Endocrinology, Department of Medicine, New York University School of Medicine, New York, New York, USA.

Clinical Pharmacology and Therapeutics
|May 15, 2015
PubMed

Insights

Strategies targeting the receptor for advanced glycation endproducts (RAGE) and its interaction with mDia1 may offer new ways to prevent diabetes and its complications. This approach is crucial given the rising global diabetes rates.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pathogenesis of Diabetes

Background:

  • Global rise in Type 1 and Type 2 diabetes.
  • Hyperglycemia treatment advances exist, but risks like hypoglycemia persist.
  • Preventing diabetes complications is essential.

Purpose of the Study:

  • Review updates on the receptor for advanced glycation endproducts (RAGE) in diabetes pathogenesis.
  • Discuss RAGE signaling mechanisms, including its interaction with mDia1.
  • Evaluate RAGE-directed therapeutics for diabetes and its complications.

Main Methods:

  • Literature review of RAGE biology in diabetic complications.
  • Analysis of mouse models for obesity and diabetic complications.
  • Examination of human associative studies.
  • Discussion of RAGE/mDia1 interaction in signal transduction.

Main Results:

  • RAGE is implicated in micro- and macrovascular complications of diabetes.
  • The RAGE/mDia1 interaction influences RAGE signal transduction.
  • Insights gained from animal models and human studies.

Conclusions:

  • Targeting RAGE/mDia1 may yield novel therapeutics for diabetes prevention.
  • RAGE-directed therapies hold promise for managing diabetic complications.
  • Further research into RAGE signaling is warranted.

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

6.4K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K